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SUMMARY
Natural genetic diversity offers an important yet largely untapped resource to decipher the molecular mechanisms regulating hemato-
poietic stem cell (HSC) function. Latexin (Lxn) is a negative stem cell regulatory gene identified on the basis of genetic diversity. By using
an Lxn knockout mouse model, we found that Lxn inactivation in vivo led to the physiological expansion of the entire hematopoietic
hierarchy. Loss of Lxn enhanced the competitive repopulation capacity and survival of HSCs in a cell-intrinsic manner. Gene profiling of
Lxn-null HSCs showed altered expression of genes enriched in cell-matrix and cell-cell interactions. Thrombospondin 1 (Thbs1) was a
potential downstream target with a dramatic downregulation in Lxn-null HSCs. Enforced expression of Thbs1 restored the Lxn inactiva-
tion-mediated HSC phenotypes. This study reveals that Lxn plays an important role in the maintenance of homeostatic hematopoiesis,
and it may lead to development of safe and effective approaches to manipulate HSCs for clinical benefit.
INTRODUCTION
Hematopoietic stem cells (HSCs) persist throughout life to
produce hematopoietic progenitor cells (HPCs) and all
types of blood cells. In the adult, HSCs reside in bone
marrow (BM), are rare but have the unique capability
for self-renewal and multilineage differentiation (Eaves,
2015). The maintenance of a steady-state HSC pool adept
at dynamic change in response to stress depends on the bal-
ance of self-renewal, differentiation, survival, and prolifer-
ation (Goodell et al., 2015). Loss of this balance could lead
to an overexpansion or exhaustion of HSC population, and
result in an increased risk for cancer or tissue degeneration.
HSCs have been used therapeutically in the clinic for
several decades in life-saving treatment of malignant dis-
eases and hematological disorders through BM transplan-
tation protocols (Doulatov et al., 2012). However, insuffi-
cient stem cell numbers significantly limit the efficacy
and success of these regimes. Expansion of HSCs while
maintaining their self-renewal capability has been one of
the most desired, yet elusive, goals in experimental hema-
tology and transplantationmedicine (Walasek et al., 2012).
HSC fate decisions require strict control. Multiple
signaling pathways regulate HSC functions through cell-
intrinsic and cell-extrinsic mechanisms (Rossi et al., 2012;
Gottgens, 2015). Genetic manipulation of transcription
factors and signal transduction pathways enhances HSC
expansion ex vivo (Andrade et al., 2010, 2011); these
include the homeobox gene family (Antonchuk et al.,
2002), immobilized Notch ligand (Delaney et al., 2010),
Wnt-associated prostaglandin E2 (Goessling et al., 2011),
the soluble growth factors angiopoietin-like 5 (Zheng
et al., 2012), pleiotrophin (Himburg et al., 2010; Himburg
et al., 2012), and miR-126 (Lechman et al., 2012), and the
aryl hydrocarbon receptor inhibitor (Boitano et al., 2010).
Moreover, employing an induced pluripotent stem cell
population and targeting the HSC microenvironment
hold promise for HSC expansion (Blanpain et al., 2012;
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Kunisaki and Frenette, 2012; Huang et al., 2013; Chen
et al., 2014). However, all these attempts have had limited
success clinically, due to a failure to expand sustainable and
self-renewable stem cells (Walasek et al., 2012).
Our understanding of the molecular pathways for HSC
fate decision is insufficient to allow safe manipulation of
HSCs for clinical benefit. Large natural variations in HSC
number and function exist in humans (Nathan and Orkin,
2009; Sankaran and Orkin, 2013) as well as in different
mouse strains (Jordan and Van Zant, 1998; Geiger et al.,
2001; Henckaerts et al., 2002; Abiola et al., 2003; Hsu
et al., 2007; Cahan et al., 2009; Avagyan et al., 2011).
Such natural genetic diversity is an important yet largely
unused tool for unraveling the genes and signaling net-
works associated with stem cell regulation (Van Zant and
Liang, 2009). Using this genetic diversity tool, we previ-
ously identified latexin (Lxn) as a stem cell regulatory
gene with expression that negatively correlates with HSC
number variation in different mouse strains (de Haan,
2007; Liang et al., 2007). Lxn is a negative regulator of
HSC function and works as a ‘‘brake’’ to constrain the
HSC pool to a physiological range. In addition, the canon-
ical function of Lxn protein is its inhibitory effect of
carboxypeptidase A (Liu et al., 2000; Uratani et al., 2000;
Pallares et al., 2005; Mouradov et al., 2006). Studies have
also shown that LXN has high structural similarity with
cystatin and tumor suppressor TIG1 gene, suggesting its
potential role in inflammation and transformation (Aa-
gaard et al., 2005). However, the in vivo function of Lxn
in hematopoiesis and the underlying regulatory cellular
andmolecular mechanisms remain largely elusive. Particu-
larly, when drawing upon genetic diversity to identify
genes (usually multiple ones) associated with a complex
trait (HSC number), all contributing genes are important
(Van Zant and Liang, 2009). Therefore, it warrants to
know to what extent Lxn contributes to the natural varia-
tion of the size of HSC population and how it specifically
regulates HSC function and hematopoiesis.
In this study, we showed that Lxn deletion in vivo leads
to increased numbers of HSCs, HPCs, and all blood cell
lineages. Loss of Lxn enhanced long-term repopulating ca-
pacity and survival of HSCs. Mechanistically, gene array
analysis showed that genes involved in cell-cell and cell-
matrix interaction were dysregulated in Lxn/ HSCs,
and thrombospondin 1 (Thbs1) was identified as a poten-
tial downstream target of Lxn. Thbs1 mRNA and protein
levels were significantly decreased in Lxn/ HSCs, and
ectopic expression of Thbs1 rescued the Lxn/ HSC
phenotype. Our study reveals the cellular and molecular
regulatory mechanisms of Lxn in HSC homeostasis,
and highlights the importance of Lxn-mediated intrinsic
and extrinsic cellular signaling in the control of HSC
function.
RESULTS
Lxn/ Mice Have Increased Blood Cell Numbers and
Balanced Lineage Differentiation
The constitutive Lxn knockout (Lxn/) mice were gener-
ated on the C57BL/6 background. Because Lxn gene lies
within the mitochondrial elongation factor G (Gfm1)
gene, only exons 2 to 4 were targeted for deletion to mini-
mize any potential effect onGfm1 (Figure 1A).Western blot
showed complete deletion of the LXN protein in BM,
spleen, liver, and brain without affecting GFM1 protein
expression (Figure 1B). Peripheral blood (PB) analysis of
Lxn/ mice showed a significant increase in the counts
of complete white blood cells, neutrophils, monocytes,
lymphocytes, and platelets compared with those of wild-
type (WT) mice (Figure 1C). The percentages of macro-
phages, granulocytes (Mac-1/Gr-1+), and B lymphocytes
(B220+) in Lxn/ mice showed a slight but significant in-
crease (Figure 1D), whereas the T lineage was not affected
(data not shown). These data suggest that Lxn deletion in-
creases the number of mature blood cells of both myeloid
and lymphoid lineages without skewing differentiation.
Lxn Inactivation Leads to Expansion of the HSC and
HPC Populations
Analysis of the BM compartment of Lxn/ mice showed a
significant increase in cellularity compared with WT mice
(Figure 2A), despite similar body weights (data not shown).
Using flow cytometry and immunostaining of HSCs
and HPCs (Figure 2B), we found that the absolute numbers
of HPCs, including common myeloid progenitor (CMP),
granulocyte/monocyte progenitor (GMP), and common
lymphoid progenitor (CLP) cells, were significantly
increased in Lxn/ mice (Figure 2C). Moreover, Lxn/
mice consistently presented a 56% increase in the absolute
number of HSC/HPC-enriched LSK cells (Figure 3D).
Among the LSK population, the absolute numbers of
long-term (LT)-HSCs, short-term (ST)-HSCs, and multipo-
tent progenitor cells (MPPs) were all significantly increased
in Lxn/ mice compared with WT mice (Figures 2E–2G).
These data suggest that Lxn inactivation leads to an expan-
sion of the hematopoietic stem and progenitor pool, which
contributes to the increased blood cell counts.
Lxn Inactivation Increases HSC Clonogenic and
Repopulating Capacity in a Cell-Intrinsic Manner
To define the effect of Lxn inactivation on the function of
HSCs and HPCs, we used the in vitro culture system,
including cobblestone area-forming cell (CAFC) and col-
ony-forming cell (CFC) assays, to assess the clonogenic po-
tential of HSCs and HPCs, respectively. Figure 3A shows
that the number of primitive HSCs (CAFC day 35) was
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3-fold higher in Lxn/ BM than WT BM. Moreover, the
total number of CFCs generated by Lxn/ BM cells was
increased by nearly 2-fold compared with WT cells (Fig-
ure 3B). We next evaluated the capability of Lxn/ HSCs
to reconstitute the hematopoiesis of myeloablated mice
by a competitive repopulation assay (Figure 3C). The results
showed that Lxn/ HSCs made a greater contribution to
the repopulation of PB leukocytes at both 8 weeks and
16weeks post transplantation comparedwithWTcells (Fig-
ure 3D). Analysis of PB lineage chimerism at 16 weeks
showed that the engrafted Lxn/HSCs retainedmultiline-
age differentiation potential and contributed tomore circu-
lating myeloid and B cells than the WT cells (Figure 3E).
This recapitulates the intrinsic changes of Lxn/ cells in
physiological condition (Figure 1D). Analysis of BM chime-
rism showed that mice transplanted with Lxn/ cells pre-
sented with 66.4% (±9.9%) donor-derived cells, whereas in
mice receiving WTcells, the contribution was dramatically
lower at 30.9% (±16.9%) (Figure 3F). In the BM LSK
compartment, the percentage and absolute number of
Lxn/-derived LSK cells was nearly 3-fold higher than
that of WT-derived cells (Figures 3G and 3H, respectively).
Altogether, these results reinforce findings of increased
numbers of functional HSC and HPC, as measured by their
Figure 1. Lxn Inactivation Increases Peripheral Blood Cell Numbers
(A) Scheme representing the Lxn gene targeting strategy. The Lxn gene lies within the Gfm-1 gene and only exons 2 to 4 of the Lxn gene
were removed to minimize any potential effect on the Gfm-1 gene.
(B) Western blot analysis of Lxn and Gfm-1 protein from the indicated organs of Lxn/ and WT control mice.
(C) Differential blood cell counts of Lxn/ and WT mice. Statistically significant differences are: ***p < 0.001, **p < 0.01.
(D) Lineage differentiation analysis by immunostaining and flow cytometry of Lxn/ and WT myeloid cells (MAC1/GR1+) and B lym-
phocytes (B220+). *p < 0.01. Presented data in (C and D) are the mean ± SD from three independent experiments (n = 22 in Lxn/, n = 20
in WT mice).
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clonogenic activity in Lxn/ mice. The data suggest that
Lxn inactivation significantly enhances HSC long-term
reconstitution capacity and maintains multilineage differ-
entiation potential in a cell-intrinsic manner. Moreover,
the extent of expansion of Lxn/-derived LSK population
in this transplantation setting (3-fold) is higher than that
in in situ condition (1-fold, Figure 2D), indicating the
likelihood of increased self-renewal of Lxn/HSCs. Future
studies are needed to address this by the serial transplant-
ability of Lxn/ HSCs.
Figure 2. Lxn Inactivation Expands the Immunophenotypically Defined HSCs and HPCs
(A) Total femoral BM cell counts (cellularity) of Lxn/ (n = 22) and WT (n = 20) mice. **p = 0.002.
(B) Representative FACS plots for HSC and HPC cell populations, including HSC and HPC-enriched LSK cells, HSC subsets (LT-HSCs, ST-HSCs,
and MPPs), myeloid committed progenitor cells (CMPs, GMPs, and MEPs), and common lymphoid progenitor cells (CLPs). Cell surface
makers for identification of each cell populations are indicated.
(C) Absolute number of CMPs (*p = 0.03), GMPs (*p = 0.02), MEPs, and CLPs (*p = 0.04) in one femur of an Lxn/ and a WT mouse.
(D) Absolute number of LSK cells in one femur of an Lxn/ and a WT mouse. *p = 0.046.
(E–G) Absolute number of LT-HSCs (**p = 0.003), ST-HSCs (*p = 0.02), and MPP cells (*p = 0.048) in one femur of an Lxn/ and a WT
mouse.
Presented data in (A–G) are the average ± SD pooled from three independent experiments with three mice per experiment for both strains
(n = 9 each strain).
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Figure 3. Lxn Inactivation Increases the Number of Functional HSCs and HPCs, and Enhances the Competitive Repopulation
Capacity of HSCs
(A) Absolute number of clones, defined by the cobblestone area-forming cell (CAFC) assay, at d35 of culture for HSC cells from Lxn/ and
WT mice (***p = 0.0002).
(B) Absolute number of clones, defined by colony-forming cell (CFC) assay, at day 14 of culture for HPC cells from Lxn/ and WT mice
(*p = 0.01). Presented data are the average ±SD pooled from three independent experiments with three mice per experiment for both
strains (n = 9 each strain).
(C) Experimental scheme for competitive repopulation assay.
(D–H) Frequencies of Lxn/ or WT donor (CD45.2)-derived leukocytes at 4, 8, and 16 (***p < 0.001) weeks after transplantation in
the PB of recipient mice (CD45.1). At 16 weeks after transplantation in the BM of recipient mice, frequencies of Lxn/ or WT donor
(legend continued on next page)
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Lxn Inactivation Enhances HSC Survival without
Affecting Cell Cycling
The HSC pool size is maintained by the balance of
apoptosis and proliferation. Apoptosis analysis with An-
nexin V showed that the percentage of Annexin V+ propi-
dium iodide-negative (PI–) apoptotic cells (Figure 4A) was
significantly decreased by nearly 50% in Lxn/ LSK cells,
and subsets of HSCs (LT-HSCs, ST-HSCs, and MPPs)
compared with the WT cells (Figure 4B). Increased survival
was further confirmed by flow cytometric analysis of LSK
cells positive for active caspase-3 (Figure 4C). The percent-
age of positive cells was significantly lower in Lxn/ mice
than that in WT mice (Figure 4D). Moreover, expression of
active caspase-3, as measured by the mean fluorescence in-
tensity, was lower in Lxn/ LSK cells than inWTcells (Fig-
ure 4E). These data suggest that Lxn inactivation can intrin-
sically enhance HSC survival. We further followed the
response of WT and Lxn/ HSCs to 5-fluorouracil (5-FU)-
induced hematopoietic stress, and found that LSK cells
in Lxn/ BM recovered faster than that in WT mice
(CD45.2)-derived (E) myeloid cells (M/G; *p = 0.02), T and B lymphocytes (***p < 0.001), (F) BM nucleated (***p < 0.001), and (G) LSK
cells (***p < 0.001), as well as (H) absolute numbers of LSK cells in one femur (***p < 0.001), were measured.
Presented data in (D–H) are the average ± SD pooled from two independent experiments with five recipients receiving either Lxn/ or WT
BM cells per experiment (n = 10 per donor group).
Figure 4. Lxn/ HSCs have Increased
Survival
(A) Representative FACS plots of Annexin V+
and 7-AAD apoptotic LT-HSCs (left plots).
Thymocytes were used as control to deter-
mine the Annexin V+ population, as we
published previously (Liang et al., 2007).
(B) Percentage of apoptotic cells in pop-
ulations of LSK cells, MPPs, ST-HSCs, and LT-
HSCs of Lxn/ and WT mice. Presented data
are the average ± SD of five mice/group.
(C) Representative flow cytometry profile of
active caspase-3 immunofluorescence signal
in LSK cells.
(D) Frequency of LSK cells positive for active
caspase-3 (*p = 0.04).
(E) The level of the active caspase-3 protein
in LSK cells of WT and Lxn/ mice. Shown is
the histogram of active caspase-3 protein
in flow cytometry analysis. Data were the
average of three independent experiments
with three mice in each one (n = 9).
(F) Lxn/ mice had a faster recovery in LSK
cells after 5-FU-induced hematopoietic stress
at days 1, 3, 6, 10, and 14.
(G) Less Lxn/ LSK cells underwent
apoptosis at 24 hr after 5-FU injection.
Data were the average of five mice at each
time point in each group. ****p < 0.0001,
***p < 0.001, **p < 0.01, and *p < 0.05.
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(Figure 4F), and less Lxn/ LSK cells underwent apoptosis
(Figure 4G). These results indicate that Lxn deletion
protects hematopoietic stem/progenitor cells from 5FU-
induced myelosuppression by enhancing their survival.
We next examined the cell-cycle status with Ki-67/PI
staining and bromodeoxyuridine (BrdU) incorporation,
and did not observe any significant difference in cell-cycle
distribution and cycling dynamics between Lxn/ andWT
LT-HSCs (Figures S1A and S1B, respectively). This result
suggests that Lxn did not affect stem cell cycling under
physiological conditions.
Lxn/ Mice Do Not Develop Hematological
Malignancy during Aging
We and others have shown that Lxn is downregulated in
leukemia, lymphoma, and several other cancers (Li et al.,
2011; Liu et al., 2012;Mitsunaga et al., 2012; Abd Elmageed
et al., 2013; Muthusamy et al., 2013; Ni et al., 2014). Since
young Lxn/ mice did not show any obvious sign of
hematological malignancy, we asked whether aging could
promote tumor development in Lxn/ mice. Cohorts
of Lxn/ and WT mice were physiologically aged for
28 months and the hematopoietic profile in PB and BM
was analyzed. No significant difference in either complete
or differentiated blood cell counts was identified between
aged-matched Lxn/ and WT mice (Figure 5A). Lineage
differentiation in old Lxn/ mice showed a slight but sig-
nificant increase in myeloid lineage and decrease in B lym-
phocytes (Figure 5B), although both strains demonstrated
age-associated myeloid skewing and immunodeficiency
compared with their young counterparts (Figure 1D). No
significant difference was found in BM cellularity (Fig-
ure 5C) and the number of CFCs (Figure 5D). Aged Lxn/
mice had nearly 2-fold more LT-HSCs in both frequency
and absolute numbers than age-matchedWTcounterparts,
but no significant difference was observed in other HSC
sub-populations (Figures 5E and 5F). Importantly, the over-
all health of old Lxn/mice was comparable with the con-
trols, and no apparent pathological changes were detected
in blood, BM, spleen, and liver of Lxn/ mice (data not
shown). These data suggest that Lxn/mice are not inher-
ently prone to hematological malignancy.
Figure 5. Aged Lxn/ Mice Do Not
Spontaneously Develop Hematologic Ma-
lignancy
In age-matched old Lxn/ and WT mice, the
following hematopoietic phenotypes were
measured.
(A) Differential blood cell counts.
(B) Lineage differentiation analysis of
myeloid cells (M/G; *p = 0.02) and T and B
lymphocytes (*p = 0.03).
(C) Total BM cell counts (cellularity).
(D) Absolute number of CFC progenitor cell
clones on day 14 of culture.
(E) Frequency of LSK cells, LT-HSCs (*p =
0.02), ST-HSCs, and MPPs in one femur.
(F) Absolute number of LSK cells, LT-HSCs
(*p = 0.02), ST-HSCs, and MPPs in one femur.
Presented data in (A–F) are the average ± SD
pooled from Lxn/ (n = 15) and WT (n = 19)
mice.
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Thbs1 Is a Downstream Target of Lxn
We performed gene array analysis in phenotypically
defined LT-HSCs and MPPs, respectively, to determine
Lxn inactivation-induced molecular changes. A total of
3,561 genes are differentially expressed, among them
one-third (1,235) are upregulated and two-thirds (2,326)
are downregulated. Gene set enrichment analysis (GSEA)
showed alteration in six signaling pathways enriched in
Lxn/ cells, and three of them involved cell-cell and cell-
extracellular matrix interaction (Figure S2A). Among the
top ten up- and downregulated genes (Figure S2B), Thbs1
is one of the most interesting candidates. The rationale is
thatThbs1 is amultidomainmatrix glycoprotein that inter-
acts with numerous adhesion receptors and proteases, and
mediates cell-cell and cell-matrix interactions (Adams and
Lawler, 2011). Thbs1 has been shown to enhance cell sur-
vival and regulate hematopoietic progenitor recovery un-
der stress conditions (Isenberg et al., 2008). These functions
are consistent with the functional effects of Lxn (You et al.,
2014), which prompted us to further investigate whether
Thbs1 is the downstream target of Lxn. Our microarray
data showed a significant decrease in Thbs1 expression in
Lxn/ HSCs. Quantitative real-time PCR validated the
downregulation of Thbs1; a reduction in mRNA expression
of at least 2-fold was identified in different subsets of
Lxn/ HSCs (Figure 6A). It is noteworthy that the expres-
sion level of Thbs1 increased with the content of primitive
hematopoietic cells, reaching the highest in themost prim-
itive HSC population. Such expression pattern is similar
to that of Lxn, as we reported previously (Liang et al.,
2007), further corroborating the association between
Thbs1 and Lxn. THBS1 protein, measured by western blot,
also decreased in Lxn/HSC/HPC-enriched Lin– cKi+ cells
(Figure 6B, left). THBS1 is a secreted protein (Adams and
Lawler, 2011). We therefore measured its level in BM fluid
and found that Thbs1 content in the Lxn/ BMmicroenvi-
ronment was also reduced (Figure 6B, right). Immunofluo-
rescence staining of THBS1 protein level in BM sections of
Lxn/ mice confirmed reduced protein content of THBS1
(Figure 6C). Furthermore, Figure 6D shows that the
THBS1 protein content was reduced in individual Lxn/
LSK cells compared withWTones (left), and the percentage
Figure 6. Thbs1 Is the Downstream Target
of Lxn
(A) Real-time PCR data demonstrating Thbs1
mRNA levels in LSK, MPP, and HSCs. **p <
0.01 and *p < 0.05. HSCs are the combination
of both LT-HSC and ST-HSCs (Lin– Sca1+
c-Kit+ Flt3 cells). Presented data are the
average ±1 SD of 12 measurements derived
from three separate samples.
(B) Western blot analysis of Thbs1 protein
in BM LIN-C-KIT+ (LK) cells and BM fluid.
Actin (ACT) was normalization control. Blots
are representative of three independent
experiments.
(C) Immunofluorescence staining of the
Thbs1 protein (red) in BM sections from
Lxn/ and WT mice. Scale bars, 50 mm.
(D) Immunofluorescence staining of Thbs1
protein (green) in individual Lxn/ or WT
LSK cells (left panel) and quantification of
LSK cells positive for Thbs1 staining (right
panel). All cells (50–100) in the field were
captured and analyzed in each sample. Scale
bars, 5 mM. ***p = 0.0003.
(E) Thbs1 heterozygous knockout mice
(Thbs1+/) had reduced THBS1 levels. West-
ern blot was performed on LSK cells
and shown is one representative blot of two
replicates.
(F) Increased number of LSK cells in
Thbs1+/ BM. BM cells from Thbs1+/ mice
were flow cytometrically analyzed for the LSK population. Data shown are the mean ±1 SD. **p = 0.01.
(G) Increased number of long-term colony-forming cells (CAFC day 35) in Thbs1+/ BM. Data shown are the mean ±1 SD. ***p = 0.003.
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of Thbs1+ LSK cells was significantly decreased in Lxn/
BM cells compared with that in WT cells (right).
To further confirm the positive correlation between Lxn
and Thbs1 expression, we overexpressed Lxn in WT LSK
cells, and found that Thbs1 mRNA level was significantly
increased (Figure S3). Moreover, we analyzed BM HSCs in
Thbs1+/ mice in which THBS1 protein was decreased (Fig-
ure 6E), and found that the number of LSK cells and CAFC
day 35 cells was significantly higher in Thbs1+/ BM than
those in WT BM cells (Figures 6F and 6G), a phenotype
similar to Lxn/ mice (Figures 2D and 3A). These data
strongly suggest that Thbs1 is a downstream target of Lxn.
Thbs1 is a natural inhibitor of angiogenesis, megakaryo-
poiesis, and thrombopoiesis (Adams and Lawler, 2011), all
of which have been shown as critical niche components
implicated in HSC regulation (Kfoury and Scadden, 2015;
Schepers et al., 2015; Bruns et al., 2014; Zhao et al.,
2014), We asked whether the reduced Thbs1 levels in
Lxn/ HSCs and surrounding environment could affect
these niche components. There was no significant differ-
ence in the number of megakaryocytes andmegakaryocyte
progenitor cells in Lxn/ mice (Figures S4A and S4B,
respectively) compared with WT mice. No difference in
the expression of von Willebrand factor and CD41, two
megakaryocyte markers, was shown in the microarray of
Lxn/ cells (data not shown). Moreover, the number of
endothelial cells and the function of platelets also remain
unchanged in Lxn/ mice (Figures S4C and S4D, respec-
tively). Altogether, these data suggest that Thbs1 is a spe-
cific downstream target of Lxn, and the decreased level of
Thbs1 might affect Lxn/ HSCs in a cell-intrinsic manner.
Enforced Expression of Thbs1 Reverts the Lxn/ HSC
Phenotype
To directly address the involvement of Thbs1 in the HSC
phenotype of Lxn/ mice, we overexpressed Thbs1 in
WT and Lxn/ LSK cells (Figures 7A and S5). Quantitative
real-time PCR and western blot analysis confirmed
increased expression of Thbs1 at both transcript and pro-
tein levels in Lxn/ cells transduced with a Thbs1 virus
compared with cells transduced with empty vector (Figures
7B and 7C, respectively). Figure 7D showed that Thbs1
overexpression dramatically reduced the number of Lxn/
HSCs assessed by CAFC at day 35. Moreover, when Thbs1-
overexpressing Lxn/ stem cells were transplanted into
myeloablated recipients, they showed a significant lower
Figure 7. Overexpression Thbs1 Rescues
Lxn/ Hematopoietic Phenotype
(A) Experimental scheme for lentivirus-
mediated Thbs1 overexpression strategy in
LSK cells.
(B and C) Quantitative real-time PCR (B)
and western blot analysis (C) of Thbs1 mRNA
and protein, respectively, in Thbs1-over-
expressing (Thbs1) Lxn/ LSK cells. Actin
(ACT) was normalization control (Con).
Blots are representative of two independent
experiments. ***p < 0.001.
(D) Absolute number of HSC clones, defined
by CAFC day 35 in Thbs1-overexpressing
(Thbs1) Lxn/ LSK cells. ***p < 0.001.
(E) Frequencies of Thbs1-overexpressing
(Thbs1) or control Lxn/ donor cells from
(GFP+)-derived PB leukocytes in recipient
mice. *p = 0.04.
(F) Absolute number of BM LSK cells, re-
populated by Thbs1 overexpression (Thbs1),
or in control Lxn/ donor cells (GFP+) from
transplantation recipient mice. **p = 0.009.
Presented data in (C–F) are the average ± SD
pooled from two independent experiments
with five recipients receiving GFP+ cells per
experiment (n = 10 per donor group).
(G) Model of regulation of HSC function by the Lxn-Thbs1 pathway. Deletion of the HSC regulatory gene, Lxn, causes downregulation of
Thbs1 mRNA and protein in stem cells, which may lead to the decreased level of active caspase-3. As a result, Lxn/ HSCs have an
enhanced survival. Decreased level of Thbs1 in the BM environment may affect HSC-niche interaction, which may lead to the increased
repopulating capacity of HSCs. Increased survival and function may contribute to the expansion of HSC pool.
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capacity to reconstitute recipients’ PB than control Lxn/
cells at 16 weeks post transplantation (Figure 7E). Consis-
tently, Thbs1 overexpression reduced the BM LSK cell
reconstitution by nearly 2-fold (Figure 7F), which reverted
the increased repopulation capacity seen in Lxn/ HSCs
(Figures 3D and 3G). However, we did not see any signifi-
cant change in CAFC day 35 number in Thbs1-overexpress-
ing WT cells, suggesting Thbs1 as a specific downstream
target of Lxn (Figure S5). Overall, the data indicate that en-
forced Thbs1 expression can revert the Lxn/ phenotype,
suggesting that the functional effect of Lxn may act, in
part, through Thbs1.
DISCUSSION
Lxnwasoriginally identifiedby thenatural variationofHSC
numbers between C57BL/6 and DBA/2 mice, in which the
C57BL/6 strain had a lower HSC number than the DBA/2
strain (Liang et al., 2007). Lxn expression negatively corre-
lates with this variation, that is, its expression is higher in
C57BL/6HSCs thanDBA/2 stemcells. However, the specific
role of Lxn in hematopoiesis remains largely unknown.
In this study, we determined the in vivo function of Lxn
in regulating HSC function and maintaining homeostatic
hematopoiesis, and uncovered the cellular and molecular
mechanisms that control these processes. Using the Lxn
knockout mouse model generated on the C57BL/6 back-
ground, we found that loss of Lxn in vivo led to an expan-
sion of the entire hematopoietic hierarchy, from the stem
cell pool to the PB cells. Very interestingly, the increased
number of HSCs in Lxn/ mice is comparable with that
of the DBA/2 strain (Liang et al., 2007), suggesting that
Lxn, as the natural regulator, has the unique characteristic
of maintaining the physiologic range of the HSC pool
size. Therefore, reduction or even deletion of Lxn activity
results in a controlled expansion of HSCs without impair-
ment of stem cell repopulating andmultilineage differenti-
ation capacity. Indeed, the transplantation studies show
that Lxn/ HSCs have a much better long-term repopula-
tion capacity with a balanced output of blood cells. More-
over, controlled expansion reduces the risk of malignant
hyperplasia, supported by the observation that Lxn/
mice did not spontaneously develop hematologic malig-
nancy even during aging. Altogether, antagonism of Lxn
function may have a therapeutic potential through a
controlled expansion of HSCs without exhaustion or
transformation.
The molecular mechanisms by which Lxn regulates HSC
function remain largely unknown. Here, we provide strong
evidence to support Thbs1 as a downstream target that me-
diates control of HSC by Lxn: (1) loss of Lxn dramatically
decreased Thbs1 mRNA and protein levels; (2) ectopic
expression of Lxn significantly increased Thbs1 transcript
level; (3) Thbs1+/ mice phenocopied Lxn/ mice in their
BM HSC population by showing an enlarged HSC pool;
and (4) ectopic expression of Thbs1 reverted the Lxn/
HSC phenotype. Thbs1 is a multidomain adhesive glyco-
protein that mediates cell-cell and cell-matrix interactions
(Adams and Lawler, 2011). It interacts with a wide range
of cell adhesion receptors and numerous proteases, and is
involved in various cellular processes, such as inhibition
of angiogenesis, megakaryocytopoiesis, and platelet func-
tion (Yang et al., 2003; Kopp and Rafii, 2007; Isenberg
et al., 2009). However, our results indicate that decreased
expression and secretion of Thbs1 in Lxn/ HSCs and sur-
rounding environment does not alter these niche cellular
components; Since Thbs1 is a matrix protein, one of the
regulatory mechanisms of Lxn may involve cell-cell and/
or cell-niche interactions by altering the abundance of ma-
trix proteins (Figure 7G). This discovery is consistent with a
previous report from the Furukawa group, although they
identified different adhesion molecules: N-cadherin, Tie2,
and Roundabout 4 (Mitsunaga et al., 2012). This discrep-
ancy may be due to the reasons that they used a less prim-
itive cell population (SCA-1+) for proteomic analysis and/
or they deleted the entire Lxn gene in the knockout mouse
model. Nevertheless, additional investigations on the role
of Lxn in stem cell trafficking, including mobilization and
homing would be valuable.
Thbs1 can induce apoptosis via upregulation of active
caspase-3 (Li et al., 2003). Consistently, Lxn/ HSCs
demonstrated decreased apoptosis and reduced levels of
active caspase-3, suggesting that downregulation of Thbs1
might also intrinsically enhance Lxn/ stem cell survival
(Figure 7G). An increased survival could boost stem cell
tolerance to genotoxic or cytotoxic stress. Indeed, absence
of Thbs1 confers near complete resistance to injury from
high-dose radiation, partly through mitigation of radia-
tion-induced BM cell apoptosis (Isenberg et al., 2008;
Soto-Pantoja et al., 2013). Moreover, Thbs1 knockout
mice demonstrated an accelerated hematopoietic recovery
following 5-FU-induced myelosuppression (Kopp et al.,
2006). Interestingly, our published work has shown that
Lxn is involved in radiation response and it increases the ra-
diation sensitivity of myeloid progenitor cells (You et al.,
2014). Therefore, we speculate that loss of Lxnmay protect
HSCs from radiation- and/or chemotherapy-induced mye-
losuppression and long-term damages. We indeed showed
that Lxn/mice had amuch faster recovery in hematopoi-
etic stem/progenitor cells from 5-FU-induced stress.
HSCs have served as a fundamental model for the study
of stem cell biology and as a vital therapeutic modality
for the treatment of hematopoietic malignancies and BM
failure syndromes (Daley, 2012; Doulatov et al., 2012).
Our results show that inhibition of Lxn activity leads to
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the controlled expansion of HSC population without
impairment of self-renewal capacity and induction of ma-
lignant hyperplasia. Therefore, Lxn might be a promising
genetic target for HSC expansion. More importantly, since
Lxn was identified by the genetic diversity underlying HSC
natural variations, it is highly likely that Lxnmay function
similarly in humans and manipulation of Lxn activity
could provide translational impact (Van Zant and Liang,
2009; Doulatov et al., 2012).
EXPERIMENTAL PROCEDURES
Animals
C57BL/6 mice and B6.SJL/BoyJ (CD45.1) recipient mice were pur-
chased from The Jackson Laboratory. Latexin constitutive
knockout mice (Lxn/) were generated by TaconicArtemis.
Thbs1 heterozygous knockout mice (Thbs1+/) were kindly pro-
vided by Dr. Shuxia Wang (Li et al., 2016; Maimaitiyiming et al.,
2016). All mice used were 8–12 weeks old. Mice were housed in
the University of Kentucky animal facilities following NIH-
mandated guidelines for animalwelfare andwith IACUCapproval.
Complete blood count was performed on a Hemavet 950 (Drew
Scientific). 5-FU was intraperitoneally injected at a concentration
of 100 mg/kg body weight.
Immunostaining and Flow Cytometry
HSCs, HPCs, and stromal cells: BM cells were stained with lineage
antibodies, including CD5 (clone 53–7.3), CD8a (clone 53–6.7),
CD45R/B220 (clone RA3-6B2), CD11b/MAC-1 (clone M1/70), LY-
6G/GR-1 (clone RB6-8C5), and TER119/Ly-76 (clone TER-119)-
APC-Cy7, and stem cell markers, C-KIT-APC, SCA-1-PE-Cy5.5,
CD34-FITC, and FLT3-PE. HPCs were stained with FcgR and
IL7R. HSC/HPC-enriched LSK cells, LT-HCSs and ST-HSCs, MPPs,
and HPCs, including CMP, GMP, megakaryocyte/erythroid pro-
genitor (MEP) and CLP cells were immunophenotypically defined
as different markers. BM megakaryocytes and endothelial cells
were stained with CD41 (clone MWR/REG30) and CD31 (clone
MEC13.3), respectively. Dead cells were excluded by PI selection.
PB lineage chimerism staining was stained with CD45.2 and
CD45.1 markers and MAC-1/GR1, THY1, and B220 markers.
Cell-cycle analysis was performed using Ki-67 and 7-aminoactino-
mycin D (7-AAD) staining. In vivo BrdU incorporation was used to
study cell-cycle dynamics. BrdU was administered in drinking
water (0.5mg/mL) for 3 days and the percentage of BrdU+ LT-HSCs
was analyzed daily. Apoptosis was performed with Annexin V and
7-AAD. Antibodies were purchased from eBioscience, BioLegend,
or BD Pharmingen. Negative controls for fluorescence-activated
cell sorting (FACS) gating was set by cells without any antibody
staining. Flow cytometry was performed on a FACSAria II (Becton
Dickinson) and the data were analyzed using FlowJo software
(TreeStar).
In Vitro Colony Assays
(1) CFC assay was performed as described previously in complete
MethoCult medium (STEMCELLTechnologies), Colony formation
was observed on days 7 and 14 (Liang et al., 2005). (2) CAFC assay
was performed as described previously (Liang et al., 2007). The
most primitive HSCs showed cobblestones at day 35, whereas
HPCs show colonies at early dates, such as CAFC day 7. CAFC fre-
quencies were calculated by using L-CaLc limiting dilution anal-
ysis software (STEMCELL Technologies).
BM Transplantation
In competitive repopulation assays, 1 3 106 donor cells from
Lxn/ or WT BM (CD45.2) mice were mixed with an equal
number of competitor BM cells (B6.SJL/BoyJ) and retro-orbitally
injected into lethally irradiated (9 Gy) recipient mice. For trans-
plantation of Thbs1-overexpressing Lxn/ cells, sorted 1 3 105
GFP+ cells that were either Thbs-1 overexpression or empty vector
control Lxn/ BM cells were mixed with 23 105 competitor cells,
and injected into B6.SJL/BoyJ recipientmice. Percentages of donor
(CD45.2 or GFP+)-derived PB and BM cells were determined at
16 weeks post transplantation (Liang et al., 2007).
Microarray Analysis
Microarray was performed on LT-HSCs andMPPs in theMicroarray
Facility Center at the University of Kentucky. In brief, nearly
100,000 LT-HSCs and MPPs were sorted from pooled marrows of
10–20 WT or Lxn/ mice. Total RNA was extracted using RNeasy
Kit (QIAGEN) and processed onto the Affymetrix Gene Chip
MoGene-1_0-st-v1 Arrays. Three independent samples were ob-
tained from each strain. Microarray data were normalized by the
robust multiarray averaging method. The limma package (Smyth,
2004) in R/Bioconductor was used to determine the differentially
expressed genes. In GSEA (Subramanian et al., 2005) (www.
broadinstitute.org/gsea/index.jsp), genes were preranked based
on the absolute values of their limma test statistics. Pathways in
the Kyoto Encyclopedia of Genes and Genomes database were
investigated. Enriched pathways were identified with false discov-
ery rate less than 0.2.
mRNA and Protein Quantification
Quantitative real-time PCR was performed as described previously
(Liang et al., 2007) with a commercially available primer/probe
mix for Thbs1 in ABI PRISM 7700 (Applied Biosystems). Western
blot was performed as described previously (Liang et al., 2007).
Antibodies were anti-GFM-1 (Abcam), anti-THBS-1 (Cell Signaling
Technology), anti-LXN, and anti-Actin (Sigma).
Overexpression of Thbs-1 in BM Cells
Flow cytometry sorted LSK cells fromC57/BL6 or Lxn/micewere
stimulated with cytokines including 100 ng/mL FMS-like tyrosine
kinase-3 ligand, 50 ng/mL mouse stem cell factor, 10 ng/mL inter-
leukin-3 (IL-3), and 10 ng/mL IL-6 in StemSpan SFEM (STEMCELL
Technologies). After 24 hr, the cells were transduced with lentiviral
particles encoding either mThbs1 (catalog no. EX-Mm05712-
Lv165), mLxn (catalog no. EX-Mm03695-Lv165), or its related
empty vector (catalog no. EX-NEG-Lv165), at an MOI of 100 for
6 hr at 37C. All lentiviral particles were premade and purchased
from GeneCopoeia. After 48 hr, the GFP-positive cells were sorted
for real-time PCR, western blotting, CAFC assay, and transplanta-
tion assays. In transplantation assay, 1 3 105 GFP+ cells plus
2 3 105 competitor B6.SJL/BoyJ BM cells were injected into
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B6.SJL/BoyJ mice, and GFP+ chimerism in PB and BM was
measured at 16 weeks post transplantation. The CAFC assay of
GFP+ cells was as described above.
Statistical Analysis
Data were examined for homogeneity of variances (F test), then
analyzed by Welch’s t test or one-way ANOVA with post hoc anal-
ysis by Tukey’s test. Differences were considered significant at
p < 0.05. All statistical analyses were conducted using SPSS 16.0
for Windows.
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